Ioannis P Trougakos
Overview
Explore the profile of Ioannis P Trougakos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
182
Citations
7773
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gumeni S, Lamprou M, Evangelakou Z, Manola M, Trougakos I
Cells
. 2023 Nov;
12(22).
PMID: 37998385
The modulation of insulin/insulin-like growth factor signaling (IIS) is associated with altered nutritional and metabolic states. The genome encodes eight insulin-like peptides, whose activity is regulated by a group of...
12.
Papanagnou E, Gumeni S, Trougakos I
Aging (Albany NY)
. 2023 May;
15(9):3226-3227.
PMID: 37166427
No abstract available.
13.
Simigdala N, Chalari A, Sklirou A, Chavdoula E, Papafotiou G, Melissa P, et al.
Cell Mol Life Sci
. 2023 Mar;
80(4):100.
PMID: 36933062
Deep sequencing of human tumours has uncovered a previously unappreciated role for epigenetic regulators in tumorigenesis. H3K4 methyltransferase KMT2C/MLL3 is mutated in several solid malignancies, including more than 10% of...
14.
Georgiopoulos G, Makris N, Laina A, Theodorakakou F, Briasoulis A, Trougakos I, et al.
JACC CardioOncol
. 2023 Mar;
5(1):1-21.
PMID: 36875897
Proteasome inhibitors (PIs) are the backbone of combination treatments for patients with multiple myeloma and AL amyloidosis, while also indicated in Waldenström's macroglobulinemia and other malignancies. PIs act on proteasome...
15.
Pateras I, Williams C, Gianniou D, Margetis A, Avgeris M, Rousakis P, et al.
J Transl Med
. 2023 Mar;
21(1):169.
PMID: 36869333
Background: Chemotherapy (CT) is central to the treatment of triple negative breast cancer (TNBC), but drug toxicity and resistance place strong restrictions on treatment regimes. Fasting sensitizes cancer cells to...
16.
Devasundaram S, Terpos E, Rosati M, Ntanasis-Stathopoulos I, Bear J, Burns R, et al.
Am J Hematol
. 2023 Feb;
98(5):E123-E126.
PMID: 36810791
No abstract available.
17.
Gianniou D, Sklirou A, Papadimitriou M, Pilala K, Stravodimos K, Avgeris M, et al.
Int J Mol Sci
. 2023 Feb;
24(3).
PMID: 36768927
Bladder cancer (BlCa) represents the sixth most commonly diagnosed type of male malignancy. Due to the clinical heterogeneity of BlCa, novel markers would optimize treatment efficacy and improve prognosis. The...
18.
Alexopoulos H, Trougakos I, Dimopoulos M, Terpos E
Eur J Intern Med
. 2022 Dec;
108:104-105.
PMID: 36586739
No abstract available.
19.
Alexopoulos H, Trougakos I, Dimopoulos M, Terpos E
Eur J Intern Med
. 2022 Nov;
107:7-16.
PMID: 36379820
In the COVID-19 pandemic era, antibody testing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has proven an invaluable tool and herein we highlight some of the most useful clinical...
20.
Paschou S, Karalis V, Psaltopoulou T, Charitaki I, Sklirou A, Iconomidou V, et al.
Hormones (Athens)
. 2022 Nov;
22(1):17-18.
PMID: 36369623
No abstract available.